Capital Performance Advisors LLP Neurocrine Biosciences Inc Transaction History
Capital Performance Advisors LLP
- $597 Million
- Q3 2025
A detailed history of Capital Performance Advisors LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Capital Performance Advisors LLP holds 2,465 shares of NBIX stock, worth $351,632. This represents 0.06% of its overall portfolio holdings.
Number of Shares
2,465
Previous 1,603
53.77%
Holding current value
$351,632
Previous $201,000
72.14%
% of portfolio
0.06%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
663Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$2.02 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.4 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$794 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$637 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$440 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...